Reports

Ideas That Generate Results

The biosimilars industry has been growing stupendously across the globe for the past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivid position, and is expected to evolve greatly from its current state. As per the estimations of our latest report, the global biosimilars market will grow at a CAGR of around 52% during 2010-2015.  With the governments and private players worldwide stepping into the industry, the market shows bright prospects and immense opportunities to cash in on.

According to “EPO Biosimilars Market Forecast to 2015”, the first-generation biosimilars currently dominate the market, and their second-generation is expected to grow stupendously in the future. Our report provides a thorough study of the EPO biosimilars market, and its future outlook. Erythropoietin (EPO) is among the most widely manufactured recombinant biosimilar proteins in the world. It is expected that the promising EPO biosimilars market may reach the size of US$ 275 Million by the end of 2015. Patent expirations of key epoietin drugs, such as Epogen and Procrit will spur the market growth in near future.

We have also discussed in our report the trends and drivers fuelling growth in the market. What kind of support the governments are providing to the industry and why do players prefer BLA over abbreviated pathway are among the main market trends studied. On understanding the industry’s competitive landscape, we found that Hospira and Sandoz GmbH are among the global EPO market leaders. Overall, the report aims at providing reliable and complete information about the EPO biosimilar market to clients and potential investors.